Barclays
LBRX icon

Barclays’s LB Pharmaceuticals LBRX Stock Holding History

Barclays’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$349K Buy
9,106
+178
+2% +$7.36K ﹤0.01% 3658
2026
Q2 		$290K Buy
8,928
+4,398
+97% +$129K ﹤0.01% 3509
2026
Q1 		$112K Sell
4,530
-25,685
-85% -$592K ﹤0.01% 3977
2025
Q4 		$673K Sell
30,215
-624
-2% -$10.9K ﹤0.01% 3688
2025
Q3 		$487K Buy
+30,839
New +$489K ﹤0.01% 3829

Other funds holding LBRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Barclays's LBRX Position: Q3 2026 in Review

Barclays increased its LB Pharmaceuticals (LBRX) stake by 2% in Q3 2026, buying an estimated $7.36K and bringing the position to 9,106 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

Barclays first reported a position in LBRX in Q3 2025 and has held it in 5 quarters since. The position peaked at $673K in Q4 2025. 48 funds tracked by Wall St. Rank hold LBRX as of Q3 2026.

  • Barclays held 9,106 shares of LB Pharmaceuticals worth $349K as of Q3 2026.
  • Barclays bought 178 LB Pharmaceuticals shares in Q3 2026, an estimated $7.36K.
  • LB Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3658 holding.
  • Barclays first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Barclays's LB Pharmaceuticals position peaked at $673K in Q4 2025.
  • 48 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.